Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P35716
UPID:
SOX11_HUMAN
Alternative names:
-
Alternative UPACC:
P35716; Q4ZFV8
Background:
Transcription factor SOX-11 plays a pivotal role in the regulation of gene expression, acting as a transcriptional activator. It binds cooperatively with other factors to gene promoters, enhancing transcriptional activation. SOX-11's involvement in cell survival and organogenesis, particularly in the neural tube, branchial arches, and somites, underscores its importance in developmental processes.
Therapeutic significance:
SOX-11's association with Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism highlights its potential as a therapeutic target. Understanding the role of Transcription factor SOX-11 could open doors to potential therapeutic strategies.